Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma

Future Sci OA. 2018 Jul 19;4(7):FSO322. doi: 10.4155/fsoa-2018-0049. eCollection 2018 Jul.


To identify real-world evidence on outcomes from therapies for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), we systematically reviewed literature in Medline/Embase for DLBCL/FL-related articles on real-world results published during January 2012-May 2016. Among 33 included articles, therapies included stem cell transplant (SCT) and chemotherapy, including experimental regimens. The highest overall survival rates were observed for SCT, long considered an optimal strategy following initial relapse. Prognoses were inferior among DLBCL patients receiving rituximab-based regimens rather than SCT, particularly among studies that exclusively focused on those ineligible for SCT due to age or co-morbidity. A lack of viable treatment options for DLBCL/FL patients ineligible for SCT after relapse remains a significant gap in care.

Keywords: DLBCL; FL; chemotherapy; overall survival; refractory; relapse; response; rituximab; stem cell therapy; systematic literature review.

Publication types

  • Review